Core Viewpoint - Pfizer Inc. is hosting a conference call on December 16, 2025, to provide financial guidance for the full year of 2026, inviting both investors and the public to participate [1][2]. Group 1: Conference Call Details - The conference call will take place at 8:00 a.m. EST and will be accessible via a webcast on Pfizer's investor website [1][2]. - Participants are encouraged to register in advance for the conference call, with dial-in options provided for both U.S. and international attendees [2]. - A transcript and replay of the call will be available on Pfizer's website within 24 hours and accessible for at least 90 days [3]. Group 2: Company Overview - Pfizer is committed to applying science and global resources to develop therapies that significantly improve patients' lives, focusing on quality, safety, and value in healthcare products [4]. - The company collaborates with healthcare providers, governments, and communities to enhance access to affordable healthcare worldwide [4]. - Pfizer has a long history of 175 years in the biopharmaceutical industry, emphasizing its role in advancing wellness and combating serious diseases [4].

Group 1 - The article highlights the potential of undervalued companies in the pharmaceutical industry, specifically mentioning the Metsera deal and its implications for investment opportunities [1] - Energy Transfer is identified as a company with strong fundamentals and good cash flows that has been overlooked by investors, presenting a long-term value investment opportunity [1] - The author expresses a preference for long-term value investing while also acknowledging the allure of deal arbitrage in certain high-profile mergers and acquisitions [1] Group 2 - The focus is on sectors that have been unjustly disliked, such as Oil & Gas and consumer goods, which could yield substantial returns for investors [1] - The article emphasizes the importance of understanding the businesses being invested in, with a clear aversion to high-tech and certain consumer goods sectors like fashion [1] - The author aims to build a community of investors through Seeking Alpha, sharing insights and fostering informed decision-making [1]

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Lung Fung Group Holdings Limited 龍 豐 集 團 控 股 有 限 公 司 (Incorporated in the Cayman Islands with limited liability) WA ...

Core Insights - The article discusses the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and investment opportunities in the biotech sector [1][2]. Group 1: Service Overview - Biotech Analysis Central offers a subscription service that includes a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks [2]. - The service is priced at $49 per month, with a yearly plan available at a discounted rate of $399, representing a 33.50% savings [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, is a private investor with a background in Applied Science, focusing on generating long-term value in the healthcare sector [2]. - The service aims to assist healthcare investors in making informed decisions through a range of analysis and news reports [2].

Lilly stock has reached new highs in recent days, becoming the first pharmaceutical company to hit a $1 trillion valuation https://t.co/CuRL7dPpXM ...

Core Insights - Bristol Myers Squibb has received approval from the European Commission to expand the use of its CAR T cell therapy, Breyanzi, for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton's tyrosine kinase (BTK) inhibitor [1][2][4] Group 1: Clinical Efficacy - In the TRANSCEND MCL trial, Breyanzi demonstrated an overall response rate of 82.7% and a complete response rate of 71.6% among patients treated in the third-line plus setting [2][3] - The therapy showed sustained clinical benefit, with 50.8% of patients still in response at 24 months [1][2] - The median time to first response was 0.95 months, indicating rapid efficacy [2] Group 2: Safety Profile - The safety results for Breyanzi were consistent with its established profile, with cytokine release syndrome (CRS) occurring in 61% of patients, and only 1% experiencing grade three or four CRS [3][19] - Neurologic toxicities were reported in 31% of patients, with grade three or four cases in 9% [3][19] - The majority of adverse events occurred within the first 14 days post-infusion, allowing for early resolution and adjustments to monitoring requirements [3] Group 3: Regulatory and Market Implications - This approval is applicable across all EU member states and EEA countries, marking the fourth approval for Breyanzi in Europe [4][5] - Breyanzi is also approved for other indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma [4][9] - Bristol Myers Squibb is positioned as a leader in cell therapy, with a focus on expanding treatment options for aggressive forms of non-Hodgkin lymphoma [34][36]

for more on Novo and Pharmaceutical spring and Guggenheim's biotech analyst Sheamus Fernandez. Sheamus, your take on the Novo results. Uh yeah, so I guess it's not too surprising to the overall market uh what happened here.This was a high-risisk reward clinical study for Nova Nordisk. Um it was well communicated by the company that way. But that being said, uh the company has had a lot of challenges this year, largely from competition from Eli Liy, but it also faces pretty challenging year in 2026 and poten ...

Core Insights - Harmony Biosciences announced positive results from its pivotal bioequivalence study for pitolisant gastro-resistant formulation, indicating its potential as a next-generation treatment for narcolepsy [1][2] - The company plans to submit a New Drug Application (NDA) in early 2026, targeting a PDUFA date in Q1 2027, with utility patent applications filed for exclusivity until 2044 [1][3] Bioequivalence Study Results - The pivotal bioequivalence study confirmed that 17.8mg of pitolisant gastro-resistant is bioequivalent to existing 17.8mg WAKIX tablets, with AUC and Cmax ratios of 108.46% and 99.65% respectively [2] - No new safety or tolerability issues were reported, and 100% of patients successfully initiated treatment at the therapeutic dose without the need for titration [2] Market Position and Future Developments - The progress on pitolisant gastro-resistant formulation highlights the accelerating momentum of the pitolisant franchise, which is nearing blockbuster status in narcolepsy [3] - Harmony is also developing pitolisant HD, a high-dose formulation aimed at enhancing efficacy for excessive daytime sleepiness and other symptoms in narcolepsy and idiopathic hypersomnia [3] Company Overview - Harmony Biosciences is focused on developing innovative therapies for rare neurological diseases, emphasizing a commitment to patients with unmet medical needs [19]

Core Viewpoint - Poxel SA is implementing a recovery plan to stabilize its financial situation and avoid liquidation, with new management focused on cost control and business development [3][5][6]. Recovery Plan Update - The recovery plan has been finalized, emphasizing commercial development for Imeglimine, PXL 770, and PXL 065, alongside significant cost reductions and clearing of liabilities [4][5]. - New financing commitments of up to €11.25 million from financial partners IPF and IRIS are aimed at supporting the recovery efforts [5][7]. - The plan requires approval from the Commercial Court of Lyon and will be presented to shareholders at the annual general meeting on December 11, 2025 [5][11]. Financial Structure and Capital Transactions - The recovery plan includes a capital increase with preferential subscription rights for existing shareholders, expected to be at a discount of 30% to 50% of the current share price [12][26]. - A capital increase reserved for IPF will be at a premium of 5% to 10% compared to the preferential subscription rights price [12][26]. - The restructuring aims to ensure that IPF retains approximately 29.9% of the company's share capital post-transaction [17][24]. Management and Strategic Focus - The new management team has been actively working since August to streamline operations and focus on core business areas, including potential partnerships for Imeglimine in Asia [6][9]. - The company plans to reduce administrative costs by transferring its listing to Euronext Growth, which will lower regulatory expenses [10][12]. Shareholder Engagement - A webinar is scheduled for November 26, 2025, to discuss the recovery plan and future prospects with shareholders [5][32]. - Shareholders will have the opportunity to vote on the proposed financial delegations and capital transactions during the upcoming general meeting [11][12].

Market Performance - The Tel Aviv Stock Exchange experienced a decline, with the Tel Aviv 35 Index falling by 1.15% to 3,320.72 points, and the Tel Aviv 125 Index decreasing by 1.20% to 3,359.47 points. The BlueTech Global Index also dropped by 1.36% to 574.59 points [1] - The All Bond corporate bond index saw a slight increase of 0.09% to 419.78 points. Total turnover in equities was NIS 1.54 billion, while bond turnover reached NIS 1.97 billion [1] Currency Exchange Rates - The shekel-dollar exchange rate was set 0.644% higher at NIS 3.28/$, and the shekel-euro rate increased by 0.834% to NIS 3.784/€ [2] Notable Stock Movements - Nice (Nasdaq: NICE; TASE: NICE) recorded the largest gain on the Tel Aviv 35 Index, rising by 4.60%. Other banks such as Bank Hapoalim (TASE: POLI), Mizrahi Tefahot Bank, Israel Discount Bank (TASE: DSCT), and First International Bank of Israel (TASE: FTIN1; FTIN5) also saw modest increases [2] - Conversely, Bank Leumi (TASE: LUMI) led the market decline with a drop of 0.51%. Tower Semiconductor Ltd. (Nasdaq: TSEM; TASE: TSEM) experienced the largest fall on the Tel Aviv 35 Index, decreasing by 8.37%. Other notable declines included Camtek (Nasdaq: CAMT; TASE: CAMT) down 5.22%, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) down 1.53%, Elbit Systems Ltd. (Nasdaq: ESLT; TASE: ESLT) down 3.40%, and Delek Group (TASE: DELKG) down 4.32% [3]